Gilead Announces Positive Results From Phase 3 Tropics 02 Study Of Trodelvy Versus Comparator Chemotherapy In Patients With Hr+/Her2- Metastatic Breast Cancer
By, Admin1 min read
Share
Gilead Sciences, Inc. Announced The Positive Overall Survival (Os) Results From The Phase 3 Tropics-02 Study Evaluating Trodelvy (Sacituzumab Govitecan-Hziy) Versus Comparator Chemotherapy (Physicians
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
